Back to top

messenger-rna: Archive

Zacks Equity Research

Novavax's (NVAX) COVID Vaccine Aids Growth, Overdependence Ails

Currently, Novavax (NVAX) has only one marketed product in its portfolio, its protein-based COVID-19 vaccine. However, it is lagging in competition behind mRNA-based vaccines.

PFENegative Net Change MRNAPositive Net Change NVAXNegative Net Change BNTXNegative Net Change